Mutations in IDH1/2 genes have been identified in 70–80% of World Health Organization (WHO) grade II-III gliomas, and these mutations are particularly prevalent in grade IV secondary glioblastomas (GBM) arising as a progression from lower grade tumours, suggesting such mutations may act as a driving force behind malignant progression [2,3]. Here, IDH1 is linked to neoplasm.